News
Microplastics could increase bowel cancer and depression risk

Microplastics from food packaging may damage the gut and raise the risk of bowel cancer and depression, new research suggests.
Austrian researchers made the discovery after examining stool tissue from healthy volunteers and found that the tiny particles could alter microbial activity in the gut, with some of the changes reflecting patterns previously linked with depression and bowel cancer.
Experts described the findings as “significant” and said it was the first human study to show that these plastic fragments could alter the human gut microbiome – the community of microorganisms that live in the digestive system.
Researchers from the University of Graz used stool samples from five healthy volunteers to grow gut microbiome cultures, which were then exposed to five common microplastic types – polystyrene, polypropylene, low-density polyethylene, poly(methyl methacrylate) and polyethylene terephthalate.
All samples were tested at concentrations reflecting estimated human exposure, as well as higher doses to explore possible dose-dependent effects.
Microplastics are plastic fragments as small as two micrometres – around two-thousandths of a millimetre – which enter food, water supplies and even the air as plastics degrade naturally.
Recent studies have identified microplastics in human lung tissue, maternal and foetal placental tissue, human breast milk and human blood. A growing body of research has also linked them to cancer, heart disease, dementia and lower-quality sperm.
“These findings are significant given how pervasive microplastic exposure is in everyday life,” said Christian Pacher-Deutsch, a microplastics researcher at the University of Graz and lead author of the study.
“Microplastics have been found in fish, salt, bottled water, and even tap water, meaning that most people are exposed daily through ingestion, inhalation and skin contact.
“The key takeaway is that microplastics do have an impact on our microbiome.
While it’s too early to make definitive health claims, the microbiome plays a central role in many aspects of well-being, from digestion to mental health.
“Reducing microplastic exposure where possible is therefore a wise and important precaution.”
Although total bacterial cell counts remained largely unchanged, microplastic-treated samples showed a consistent and significant increase in acidity compared with untreated ones, indicating altered microbial activity.
Further analysis showed that certain bacterial groups changed in composition depending on the microplastic type, with most changes occurring within the phylum Bacillota – a key group of gut bacteria important for digestion and overall gut health.
The researchers also discovered that some of these microplastic-related changes mirrored microbial patterns previously linked to diseases such as depression and bowel cancer.
Scientists said they were not yet certain why this occurred but suggested several possible explanations.
“For instance, biofilms can form on microplastic surfaces, providing new niches that some microbes colonise more rapidly,” said Mr Pacher-Deutsch.
“Microplastics may also carry chemical substances that directly influence bacterial metabolism.
“This can lead to changes in acid production, which may serve as a bacterial stress response, unintentionally altering the gut’s pH.”
The research will be presented in full at the United European Gastroenterology annual congress in Berlin on 7 October.
There are around 44,000 cases of bowel cancer every year in the UK and 142,000 in the US, making it the fourth most common cancer in both countries.
Symptoms often include changes in bowel movements such as persistent diarrhoea or constipation, feeling the need to poo more or less frequently and blood in the stool. Stomach pain, bloating, a lump in the abdomen, fatigue and unexplained weight loss are among other signs.
Although the vast majority of bowel cancer diagnoses affect those aged over 50, rates in younger adults have risen by about 50 per cent over the past 30 years, while figures in older age groups have remained stable or declined.
Cancer Research UK estimates that over half (54 per cent) of bowel cancer cases in the UK are preventable.
News
Gut-friendly foods may damage heart, charity warns
News
Diabetes patients face increased risk of undiagnosed heart failure

People with diabetes may have undiagnosed heart failure that could be detected by a simple screening blood test, research suggests.
The TARTAN-HF trial found that one in four patients with diabetes who had at least one other risk factor for heart failure had undiagnosed heart failure detected through screening with a blood test and ultrasound scanning of the heart.
Experts said the findings show the extent of unrecognised heart failure in people with diabetes, and how the condition can be detected using a widely available blood test called NT-proBNP, which measures how much strain the heart is under.
They suggest a heart failure screening programme for diabetics could improve diagnosis rates, lead to earlier treatment and potentially reduce the risk of hospitalisation and death.
The study, involving 700 patients, was led by the University of Glasgow in collaboration with AstraZeneca, Roche Diagnostics, Us2.ai, NHS Greater Glasgow and Clyde and NHS Lanarkshire.
Dr Kieran Docherty, clinical senior lecturer at the University of Glasgow’s School of Cardiovascular and Metabolic Health, said: “Our results from the landmark TARTAN-HF trial identified heart failure in a large proportion of people living with diabetes, emphasising the need for a heart failure screening strategy in this group of patients.
“We know that many of the symptoms and signs of heart failure are non-specific, and may go unrecognised as potentially being due to heart failure for a long time.
“The strategy used in our trial is simple and easy to implement in clinical practice, and will aid in the early identification of heart failure in people with diabetes, and facilitate the initiation of medications that we know improve outcomes in patients with heart failure.”
The study, which began more than three years ago, involved more than 700 people with diabetes from the two health board areas who had at least one other risk factor for heart failure.
They were randomly assigned either to receive heart failure screening or to continue with their usual care.
Researchers found screening uncovered a large number of previously unrecognised cases of heart failure. Around one in four, or 24.9 per cent, of those screened were found to have the condition within six months, compared with 1 per cent in the group continuing their usual care.
The study, involving patients with type 1 and type 2 diabetes, found almost all of the participants found to have heart failure had preserved ejection fraction, which can be difficult to detect without dedicated testing.
The findings of the TARTAN-HF trial were presented at the American College of Cardiology conference taking place from 28 to 30 March in New Orleans in the US.
Dr Edward Piper, medical director at AstraZeneca UK, said: “Delayed diagnosis and treatment of heart failure in people with type 2 diabetes contributes to poor long-term outcomes. TARTAN-HF demonstrates that targeted, risk-based screening can identify previously undiagnosed heart failure in approximately one in four high-risk patients with diabetes, enabling earlier intervention with guideline-directed therapy.”
Dr Christian Simon, head of global medical affairs at Roche Diagnostics, said: “We are proud to have supported the landmark TARTAN-HF trial. These findings demonstrate the transformative power of early, accessible diagnostics like the NT-proBNP blood test.
“By identifying unrecognised heart failure in people with diabetes, we enable clinicians to initiate appropriate treatments sooner, ultimately improving patient outcomes and lives.”
Wellness
UK government announces £6.3m fund to boost men’s health

The UK has launched a £6.3m men’s health fund to back local projects aimed at helping men and boys live longer, healthier lives.
The Men’s Health Community Fund is a partnership between the Department of Health and Social Care, Movember and People’s Health Trust.
The government is contributing £3m, while the two charities are more than doubling that to take the total to £6.3m.
Grants will support community projects reaching underserved men and boys aged 16 and over, particularly in the most disadvantaged areas and at key points in their lives such as becoming a father, losing a job or retiring.
Projects could include support for new fathers, activities for men facing loneliness and social isolation, services to help young men engage with the health system, and support for men in work, out of work and moving into retirement.
The programme will bring together voluntary, community and social enterprise organisations to test new ways of reaching men who are least likely to use traditional health services.
An evaluation funded through the National Institute for Health and Care Research will assess what works and help inform future policy and delivery.
Health and social care secretary Wes Streeting said: “Too many men across the country are living shorter, less healthy lives, particularly those in our most disadvantaged communities.
“This new partnership will help men get the support they need in the places they feel most comfortable, their communities, among people they trust.
“By working with expert charities and local organisations, we can reach the men who are too often missed by traditional services and help them take better care of their mental and physical health.”
“It is a key step in delivering our first ever Men’s Health Strategy and driving forward our ambition to halve the gap in healthy life expectancy between the richest and poorest areas.”
The Men’s Health Strategy sets out plans to tackle the physical and mental health challenges men and boys face.
Men can be less likely to seek help and more likely to suffer in silence, while higher rates of smoking, drinking, gambling and drug use are damaging men’s health and affecting families, workplaces and communities.
The government is also investing £3.6m over the next three years in suicide prevention projects for middle-aged men in local communities across areas of England where men are most at risk, many of which are also among the most deprived. Suicide is one of the biggest killers of men under 50, and three-quarters of all suicides are men.
The projects will aim to break down barriers middle-aged men face in seeking support, including stigma around asking for help and a lack of awareness of what is available and how to access it.
They will be co-designed with experts and men with lived experience of mental health crises and suicidal thoughts.








